文献速递肝病消化道肿瘤与早癌

美国终末期肝病住院患者的姑息治疗可及性

Palliative care access for hospitalized patients with end-stage liver disease across the United States.
PubMed 文献 · Hepatology · 2017-09-26

基于美国全国住院患者样本2006—2012年的回顾性全国队列分析,共39,349例终末期肝病住院患者纳入分析,其中1,789例(4.5%)接受姑息治疗会诊;姑息治疗转诊率从2006年的0.97%升至2012年的7.1%(P<0.01),并观察到社会经济学、地理和种族方面的可及性障碍。

要点

  • 终末期肝病住院患者姑息治疗会诊率为4.5%,转诊率从2006年0.97%升至2012年7.1%(P<0.01)。
  • 西班牙裔种族(OR 0.77)和有保险覆盖(OR 0.74)与较低的姑息治疗转诊相关。
  • 放弃复苏状态(OR 16.24)、肝细胞癌(OR 2.00)和转移性癌症(OR 2.39)与较高的姑息治疗转诊相关。

核心结论

  • 2006年至2012年间终末期肝病患者姑息治疗使用大幅增加,但观察到社会经济学、地理和种族方面的姑息治疗可及性障碍。

研究设计与样本

  • 利用全国住院患者样本进行的回顾性全国队列分析,纳入年龄>18岁且至少发生两次肝失代偿事件的终末期肝病患者。
  • 分析2006—2012年全国住院患者样本共55,208,382例住院记录,其中39,349例(0.07%)符合研究纳入标准。

主要发现

  • 1,789例(4.5%)终末期肝病患者接受了姑息治疗会诊。
  • 终末期肝病患者姑息治疗转诊率从2006年的0.97%上升至2012年的7.1%(P<0.01)。
  • 多因素分析中,与较低姑息治疗转诊相关的因素为西班牙裔种族(OR 0.77;95%CI 0.66-0.89;P<0.01)和有保险覆盖(OR 0.74;95%CI 0.65-0.84;P<0.01)。
  • 与较高姑息治疗转诊相关的因素为年龄(每增加5岁,OR 1.05;95%CI 1.03-1.08;P<0.01)、放弃复苏状态(OR 16.24;95%CI 14.20-18.56;P<0.01)、在教学医院治疗(OR 1.25;95%CI 1.12-1.39;P<0.01)、存在肝细胞癌(OR 2.00;95%CI 1.71-2.33;P<0.01)和存在转移性癌症(OR 2.39;95%CI 1.80-3.18;P<0.01)。
  • 姑息治疗转诊在西海岸医院(OR 1.81;95%CI 1.53-2.14;P<0.01)以及大型医院(OR 1.49;95%CI 1.22-1.82;P<0.01)最为常见。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Patients with end-stage liver disease (ESLD) often have a high symptom burden. Historically, palliative care (PC) services have been underused in this population. We investigated the use of PC services in patients with ESLD hospitalized across the United States. We used the Nationwide Inpatient Sample to conduct a retrospective nationwide cohort analysis. All patients >18 years of age admitted with ESLD, defined as those with at least two liver decompensation events, were included in the analysis. A multivariate logistic regression model predicting referral to PC was created. We analyzed 55,208,382 hospitalizations from the 2006-2012 Nationwide Inpatient Sample, with 39,349 (0.07%) patients meeting study inclusion. PC consultation was performed in 1,789 (4.5%) ESLD patients. The rate of PC referral in ESLD increased from 0.97% in 2006 to 7.1% in 2012 (P < 0.01). In multivariate analysis, factors associated with lower referral to PC were Hispanic race (odds ratio [OR], 0.77; 95% confidence interval [CI], 0.66-0.89; P < 0.01) and insurance coverage (OR, 0.74; 95% CI, 0.65-0.84; P < 0.01). Factors associated with increased referral to PC were age (per 5-year increase, OR, 1.05; 95% CI, 1.03-1.08; P < 0.01), do-not-resuscitate status (OR, 16.24; 95% CI, 14.20-18.56; P < 0.01), treatment in a teaching hospital (OR, 1.25; 95% CI, 1.12-1.39; P < 0.01), presence of hepatocellular carcinoma (OR, 2.00; 95% CI, 1.71-2.33; P < 0.01), and presence of metastatic cancer (OR, 2.39; 95% CI, 1.80-3.18; P < 0.01). PC referral was most common in west coast hospitals (OR, 1.81; 95% CI, 1.53-2.14; P < 0.01) as well as large-sized hospitals (OR, 1.49; 95% CI, 1.22-1.82; P < 0.01). CONCLUSION: From 2006 to 2012 the use of PC in ESLD patients increased substantially; socioeconomic, geographical, and ethnic barriers to accessing PC were observed. (Hepatology 2017;66:1585-1591).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Rush B, Walley KR, Celi LA, et al. Palliative care access for hospitalized patients with end-stage liver disease across the United States. Hepatology. 2017. PMID: 28660622. doi:10.1002/hep.29297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。